ReviewAntioxidants (Basel, Switzerland)2024
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives.
Review in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The Evolution of Cardiac Rehabilitation from Supervised Models to New Frontiers in Digital Health.Journal of clinical medicine · 2026Review
- Modulation of the Vasopressin System in Distributive and Cardiogenic Shock: Theoretical Principles and Practical Applications.Journal of clinical medicine · 2026Review
- Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact.Journal of clinical medicine · 2026Review
- Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta-Analysis of Randomized Trials.Cardiovascular therapeutics · 2026Review
- Cognition and coronary events: A narrative overview of neurocognitive impairment in ACS patients.American heart journal plus : cardiology research and practice · 2025Review
- Protective Role of Lipid-Lowering Drugs in Breast Cancer: Effects on Cancer Incidence and Cardiotoxicity.Life (Basel, Switzerland) · 2025Review
- Takotsubo Syndrome and Cancer: Pathophysiological Links and Clinical Perspectives.Biomedicines · 2025Review
- Integrated bulk sequencing and single-cell transcriptomic profiling implicates neutrophil-driven hypoxia in atrial fibrillation development.Journal of thoracic disease · 2025Article
- Atrial Septal Defect and Heart Rhythm Disorders: Physiopathological Linkage and Clinical Perspectives.Biomedicines · 2025Review
- Factor XI and Cancer: Physiopathological Linkage and Clinical Perspectives.Journal of clinical medicine · 2025Review
- Effect of Introducing a Mini-Ergometer to the Ward Due to the COVID-19 Pandemic-Imposed Restrictions on Rehabilitation Centers on Physical Function: Cardiac Rehabilitation of Patients with Heart Failure.Journal of clinical medicine · 2025Article
- Three-Year Echocardiographic Follow-Up in Outpatients with Systemic Arterial Hypertension: An Observational Cohort Study.Journal of clinical medicine · 2025Article
- Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications.Journal of clinical medicine · 2025Review
- The Complex Relationship Between Heart Failure and Chronic Obstructive Pulmonary Disease: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.Biomedicines · 2025Review
- Takotsubo Syndrome and Oxidative Stress: Physiopathological Linkage and Future Perspectives.Antioxidants (Basel, Switzerland) · 2025Review
- Understanding LOT-CRT: Current Insights, Limitations, and Our Center's Experience.Journal of clinical medicine · 2025Review
- Iron Deficiency Treatment in Heart Failure-Challenges and Therapeutic Solutions.Journal of clinical medicine · 2025Review
- Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence.Journal of clinical medicine · 2025Review
- Short-term outpatient follow-up of vericiguat treatment in patients hospitalized for heart failure.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) and atrial fibrillation (AF) are prevalent cardiovascular diseases that contribute significantly to morbidity, mortality, hospitalisation, and healthcare costs. It is not uncommon for these conditions to coexist and have mutually reinforcing effects. A critical factor in the aetiology of these conditions is oxidative stress, driven by reactive oxygen species (ROS), which contributes to atrial remodelling and fibrosis. The recent introduction of new drugs for the treatment of heart failure has also had an impact on the management of atrial fibrillation due to their influence on oxidative stress. The objective of this review is to analyse the effects of these therapies, including their role in mitigating ROS, on the prevention and treatment of AF in HF patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.